10x Genomics has acquired Proteintech Genomics, a division within Proteintech Group, in a move aimed at expanding its capabilities in proteomics and strengthening integrated single-cell and spatial biology workflows.

The acquisition brings Proteintech Genomics’ antibody-based technologies into the 10x Genomics portfolio, including its Human Discovery Panel, which the company describes as its largest single-cell protein panel for analysing intracellular proteins, cell surface proteins and transcriptomic profiles within sequencing-compatible workflows.

Researchers are increasingly combining transcriptomic and proteomic data to gain a more comprehensive understanding of cellular function and disease biology. Integrating RNA and protein measurements has become an important approach in areas such as oncology, immunology and neuroscience, where a single data type may not provide the full biological picture.

Proteintech Genomics’ products have been developed for compatibility with 10x Genomics’ existing single-cell platforms, including Flex chemistry and the Flex Apex assay. The companies said bringing the technologies together could simplify workflows that currently require researchers to combine products from multiple suppliers.

Michael Schnall-Levin, chief technology officer, chief strategy officer and founding scientist at 10x Genomics, said: “We believe the future of biological analysis will increasingly integrate transcriptomic and proteomic information at the single cell and spatial levels. The acquisition of Proteintech Genomics expands our capabilities in proteomics and supports our broader vision for richer multiomic approaches to understanding biology.”

The deal also supports 10x Genomics’ plans to broaden multimodal biological analysis across its research platforms, including protein capabilities intended for its recently launched Atera platform.

The growing interest in multiomic technologies reflects demand for more detailed insights into cellular identity, state and function. By measuring both RNA expression and protein abundance from the same sample, researchers can generate datasets that may improve disease characterisation and biomarker discovery while supporting translational research.

Kristopher Nazor, chief executive officer at Proteintech Genomics, said: “From day one, Proteintech Genomics was built around the belief that RNA and protein measurements are most powerful when used together. Because our technologies were designed to integrate with 10x workflows, joining the 10x team feels like a natural next chapter. We are excited about the opportunity to accelerate innovation together and expand access to integrated multiomic approaches for researchers around the world.”

He added: “Single cell and spatial biology has always promised a more complete picture of cellular state – protein and RNA together, at scale, across tissues. We’re finally in a position to deliver on that promise.”

The transaction also attracted support from the wider research community. Ci Chu, senior vice president, AI-enabled discovery, at Xaira Therapeutics, said: “Biology is bigger than transcriptomics alone. Bringing scalable protein measurements into single cell and spatial biology is an important step toward richer, more predictive views of cellular state — and ultimately, virtual cell models that better reflect the complexity of living systems.”

Financial terms of the acquisition were not disclosed. 10x Genomics said it does not expect the transaction to have a meaningful impact on its near-term financial outlook.